DELFIN VALITE: Open Payments
NPI 1295794428 · BENNETTSVILLE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,840 in 132 payments from 19 companies in 2025. Trend: 2023 $2,194 · 2024 $2,579 · 2025 $2,840
Food & beverage: $2,738Education: $101
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 38 | $790 |
| Neurocrine BioSciences, Inc. | 16 | $319 |
| ABBVIE INC. | 17 | $314 |
| E.R. Squibb & Sons, L.L.C. | 12 | $279 |
| Axsome Therapeutics, Inc. | 8 | $257 |
| Otsuka America Pharmaceutical, Inc. | 12 | $240 |
| Janssen Pharmaceuticals, Inc | 6 | $164 |
| Neos Therapeutics, LP | 4 | $76 |
| Tris Pharma Inc | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
Products named: UZEDY, INGREZZA, VRAYLAR, COBENFY, Auvelity, REXULTI, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across SC — which companies pay providers there.
